Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07321886 · ClinicalTrials.gov registry record · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,980
- Enrollment target
- 20
- Study locations
NCT07321886: Recruiting Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
NCT07321886 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,980 participants, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (142% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07321886, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,980 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eloralintide
Study Locations (20)
California
- Neighborhood Healthcare Institute of Health - Escondido
- Ark Clinical Research - Fountain Valley - Fountain Valley
- Desert Oasis Healthcare Medical Group - Palm Springs
- Peninsula Research Associates - Rolling Hills Estates
- Care Access - Sacramento - Sacramento
- Southern California Clinical Research - Santa Ana
- University Clinical Investigators, Inc. - Tustin
Florida
- JEM Research Institute - Atlantis
- BioMed Research & Medical Center - Miami
- Adult Medicine of Lake County, Inc. - Mt. Dora
- American Research Centers of Florida - Pembroke Pines
- AHF Pensacola - Pensacola
- IMA Clinical Research St. Petersburg - St. Petersburg
Georgia
- Teak Research Consults - Dunwoody - Dunwoody
- Teak Research Consults - Lawrenceville
- Clinical Research Atlanta - Stockbridge
Alabama
- MFA Clinical Research - Tuscaloosa
Arizona
- Headlands Research - Scottsdale - Scottsdale
Connecticut
- Chase Medical Research, LLC - Waterbury
Hawaii
- East-West Medical Research Institute - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,980 participants |
| Start Date | 2026-02-06 |
| Est. Completion | 2030-07 |
| Phase | Phase 3 |
What NCT07321886 shows while recruiting
NCT07321886 is an interventional study that assigns participants to a tested intervention. Its 1,980 participants enrollment target places it among the larger protocols in the corpus, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (142% higher).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07321886 names 20 study sites across 7 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07321886 about?
NCT07321886 is a clinical study titled "A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes". The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants w...
What is the current status of trial NCT07321886?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,980 participants. The study started on 2026-02-06. Estimated completion is 2030-07.
What conditions does trial NCT07321886 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07321886?
The interventions under investigation include: Placebo (DRUG), Eloralintide (DRUG).
Who is sponsoring clinical trial NCT07321886?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07321886 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07321886's enrollment target sits among peer trials
1,980 47th of 1053 higher than 1,007 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062394 · 1,980 participants · NA
Penn Medicine Healthy Heart
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI